HCA Healthcare, Inc. $HCA Shares Sold by Mn Services Vermogensbeheer B.V.

Key Points

• Mn Services Vermogensbeheer B.V. reduced its stake in HCA Healthcare by 5.9%, selling 4,300 shares and holding 69,000 shares valued at approximately $26.4 million.
• Institutional investors currently own 62.73% of HCA Healthcare's stock, with notable recent acquisitions by multiple hedge funds, including Cheviot Value Management LLC and Saudi Central Bank.
• HCA Healthcare recently announced a quarterly dividend of $0.72 per share, representing an annual yield of 0.7%, with a payout ratio of 12.11% as of the last financial reporting.

Mn Services Vermogensbeheer B.V. trimmed its stake in HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 5.9% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 69,000 shares of the company's stock after selling 4,300 shares during the quarter. Mn Services Vermogensbeheer B.V.'s holdings in HCA Healthcare were worth $26,434,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Cheviot Value Management LLC acquired a new position in shares of HCA Healthcare in the 1st quarter worth $26,000. Saudi Central Bank purchased a new position in shares of HCA Healthcare during the first quarter valued at $26,000. WPG Advisers LLC purchased a new position in shares of HCA Healthcare during the first quarter valued at $27,000. Atwood & Palmer Inc. purchased a new position in shares of HCA Healthcare during the first quarter valued at $28,000. Finally, Bartlett & CO. Wealth Management LLC grew its holdings in shares of HCA Healthcare by 888.9% during the first quarter. Bartlett & CO. Wealth Management LLC now owns 89 shares of the company's stock valued at $31,000 after buying an additional 80 shares in the last quarter. 62.73% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at HCA Healthcare

In related news, EVP Michael S. Cuffe sold 3,836 shares of the business's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $418.84, for a total transaction of $1,606,670.24. Following the transaction, the executive vice president directly owned 31,503 shares in the company, valued at $13,194,716.52. The trade was a 10.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on HCA. Barclays lowered their price target on HCA Healthcare from $416.00 to $390.00 and set an "overweight" rating on the stock in a report on Monday, July 28th. Robert W. Baird lifted their price objective on HCA Healthcare from $380.00 to $423.00 and gave the company a "neutral" rating in a research report on Thursday, August 14th. Royal Bank Of Canada reduced their price objective on HCA Healthcare from $404.00 to $401.00 and set an "outperform" rating for the company in a research report on Monday, July 28th. Wall Street Zen raised HCA Healthcare from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Finally, Wells Fargo & Company reduced their price objective on HCA Healthcare from $385.00 to $375.00 and set an "equal weight" rating for the company in a research report on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat, HCA Healthcare has an average rating of "Moderate Buy" and a consensus price target of $403.17.

HCA Healthcare Price Performance

NYSE HCA opened at $398.75 on Thursday. HCA Healthcare, Inc. has a twelve month low of $289.98 and a twelve month high of $420.98. The company has a debt-to-equity ratio of 69.07, a quick ratio of 0.86 and a current ratio of 0.98. The stock has a market capitalization of $93.30 billion, a PE ratio of 16.76, a P/E/G ratio of 1.26 and a beta of 1.41. The stock has a 50-day simple moving average of $384.23 and a 200 day simple moving average of $364.54.

HCA Healthcare (NYSE:HCA - Get Free Report) last issued its quarterly earnings results on Friday, July 25th. The company reported $6.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.20 by $0.64. HCA Healthcare had a negative return on equity of 7,363.11% and a net margin of 8.21%.The firm had revenue of $18.61 billion for the quarter, compared to analyst estimates of $18.49 billion. During the same period in the previous year, the company posted $5.50 earnings per share. The company's quarterly revenue was up 6.4% compared to the same quarter last year. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. Research analysts anticipate that HCA Healthcare, Inc. will post 24.98 EPS for the current year.

HCA Healthcare Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Tuesday, September 16th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 0.7%. The ex-dividend date is Tuesday, September 16th. HCA Healthcare's payout ratio is currently 12.11%.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.